Asia pacific can be a potential market for atherectomy devices since countries such as India and china possess the largest number of cardiac patients with an annual incidence of 7 million strokes. Tobacco consumption is rapidly increasing in south Asian countries in conjunction with economic expansion increasing their risk of artery diseases.
Reduction of abdominal obesity through lifestyle measures can improve all components of the metabolic syndrome and likely delay the development of both diabetes and atherosclerosis. Beyond lifestyle intervention, optimal management of risk factors to evidence-based targets is essential.
Download Free Sample - https://www.millioninsights.com/industry-reports/atherectomy-devices-market-size/request-sample
High awareness of health problems caused due to change in lifestyle and optimal management of risk factors can improve the metabolic syndrome and likely reduce the development of both diabetes and atherosclerosis and hence reducing the demand for the atherectomy devices.
The major companies of the market include Bayer AG, Cardiovascular systems, St. Jude medical, Boston scientific corporation, Abbott laboratories, C.R Bard Inc., Volcano Corporation.
The competition in this market usually depends on the technology used in manufacturing of the devices and also the pricing strategies. Medtronic’s is leading competitor in peripheral atherectomy devices. Medtronic acquired Covedian in 2015 and is expected to remain in the leading position however it will face increasing competition from cardiovascular systems Inc.
Comments
Post a Comment